Theradaptive is pioneering advancements in therapeutic delivery through innovative protein engineering. The company focuses on transforming naturally occurring proteins into material-binding variants that enhance the efficacy and safety of therapeutics. By utilizing a proprietary computational platform, Theradaptive identifies and optimizes protein variants that can bind with high affinity to various materials. This technology allows for precise delivery of therapeutics to targeted locations within the body, significantly improving treatment outcomes while minimizing off-target effects. Their approach addresses the limitations of traditional protein therapeutics, which often lack the necessary properties for effective disease treatment.

The company has developed a range of applications for its modified proteins, targeting critical areas such as vascular, soft tissue, and orthopedic repair, as well as targeted chemotherapeutics. Theradaptive's platform has demonstrated superiority over standard care in preclinical studies, showcasing strong dose-dependent bone regeneration and complete tissue bridging in models of bone repair. By enabling long-term local delivery of therapeutics without the need for chemical modifications, Theradaptive is redefining the landscape of regenerative medicine and addressing unmet patient needs in various clinical indications.

United States

Developed a computational platform that converts recombinant proteins intomaterial-binding variants that can be used to coat implants, devices, and injectable carriers.

Theradaptive

Company Details